NVAX Earnings

NVAX reported its FY2025Q4 earnings on 2026-03-06, showcasing a revenue of against an estimate of 102.85M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.66 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following NVAX's FY2025Q4 earnings announcement on 2026-03-06, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, NVAX's stock price tends to shift by an average of 1.58% in the 10 days leading up to earnings and 14.24% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate NVAX's annual revenue to reach 114.53M, while the EPS is projected at -0.32. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between NVAX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NVAX's stock price typically moves by 1.58% in the 10 days before its earnings and 14.24% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.32 and revenue of 114.53M.

The earnings call indicates a positive outlook with increased revenue frameworks for 2025 and 2026, a strong partnership with Sanofi, and promising early-stage vaccine developments. Despite some unclear management responses in the Q&A, the market's positive sentiment is driven by raised guidance, a new Pfizer partnership, and a strategic focus on leveraging Matrix-M technology. Given the company's small-cap status, the stock price is likely to react positively, potentially experiencing a 2% to 8% increase over the next two weeks.